Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.

Ruben A. Mesa,Stacie Hudgens,Lysbeth Floden,Jeanne Palmer,Vikas Gupta,Donal McLornan,Mary Frances McMullin,Jean-Jacques Kiladjian,Lynda M Foltz,Uwe Platzbecker,María Laura Fox,Adam J. Mead,David M. Ross,Stephen T. Oh,Andrew C. Perkins,Michael F. Leahy,Samineh Deheshi,Rafe Donahue,Barbara Klencke,Srdan Verstovsek

Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.

2021

e19040Background: Clinical trials investigating JAK1/JAK2 inhibitors for myelofibrosis (MF) subjects have measured symptom improvement as a minimum 50% reduction in total symptom score (TSS) at the...

Keywords:

Total symptom score
Medicine
Internal medicine
Myelofibrosis
Ruxolitinib
Clinical trial
symptom improvement

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations